FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease

Author profile image Aggregator
0 comments
The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.

Source: NeurologyLive Published 19 Nov 2026 Imported 19 Nov 2026 Relevancy: Not reviewed

Read the article